Arovella Therapeutics Limited

Arovella Therapeutics Limited is a biotechnology company specializing in the development of cell therapies for cancer treatment. Its primary focus is on advancing an innovative platform based on invariant natural killer T (iNKT) cells, which are engineered to provide off-the-shelf immunotherapy options. The company’s leading program, ALA-101, utilizes CAR19-iNKT cells to target CD19-positive blood cancers, such as certain lymphomas and leukemias, aiming to overcome limitations of traditional CAR-T therapies by offering scalable, donor-derived solutions. Beyond hematologic malignancies, Arovella’s pipeline includes programs targeting solid tumors through new constructs and novel targets like Claudin 18.2 and cytokine-based therapeutics for broader cancer indications. Incorporated in 1999 and headquartered in Preston, Australia, Arovella Therapeutics has positioned itself within the healthcare sector at the intersection of immunotherapy and biotechnology, seeking to improve treatment accessibility and efficacy for patients with diverse, hard-to-treat cancers.